Prescription Dermatology Therapeutics Market Projected to Experience Continued Significant Growth

Prescription Dermatology Therapeutics Market – Snapshot

The global prescription dermatology therapeutics market is growing at a rapid pace due to high prevalence and increase in incidence rate of chronic and infectious dermatological disorders, and new product development and commercialization across the globe. In terms of revenue, the global market was valued at US$ 27,580.0 Mn in 2017 and is projected to reach US$ 61,296.1 Mn by 2026, expanding at a CAGR of 9.5% from 2018 to 2026. The global prescription dermatology therapeutics market is also driven by rise in adoption of biologics for the treatment of moderate to severe dermatological disorders, especially psoriasis, and large patient population with unmet medical needs across the globe.

Skin is the largest organ of the body and the first point of contact for microbes and toxins. It contains a rich habitat of microbes which results in various dysfunctions. This is where dermatology steps in. Dermatological disorders differ across the globe based on geographic location, climatic conditions, socioeconomic status, lifestyles, age, gender, heredity, and personal habits. The importance of skin has increased in the past few years. Large number of people is willing to treat various dermatological diseases due to awareness. Increase in the number of indications treated with topical drugs is projected to propel the global prescription dermatology drugs market.

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=22733

The global prescription dermatology therapeutics market is driven by intensive research to provide treatments and/or relieve the symptoms of chronic dermatological disorders. There is large patient population suffering from dermatology disorders with unmet medical needs and the number is increasing across the globe. Leading pharmaceutical companies are striving to address these unmet medical needs through new product development. Large number of both small molecules and biologic products are under different phases of clinical trials for the treatment of dermatology disorders. Companies have made significant investments in clinical R&D and have also established strategic partnerships and collaborations to accelerate new product development. For instance, as of March 31, 2018, Aurobindo Pharma had around 38 products under development in dermatology therapeutics in topical forms. Additionally, the company has around 24 products in the portfolio that need clinical trials. High prevalence and rise in incidence rates of chronic dermatological disorders with significant unmet medical needs are projected to propel the global prescription dermatology therapeutics market during the forecast period.

Posted in
identicon

Ganesh Rajput

As one of the lead news writers on CMFE News, Ganesh’s specialization lies in the science and technology domains. His passion for the latest developments in cloud technology, connected devices, nanotechnology, and virtual reality, among others, shines through in the most recent industry coverage he provides. Ganesh’s take on the impact of digital technologies across the science, technology, and business domains gives his writing a fresh and modern outlook.

Leave a Reply